An experimental gene therapy known as GC301 improved motor function and cardiac outcomes for three out of four infants with infantile-onset Pompe disease (IOPD) in a small clinical trial. The treatment was also well tolerated. One year after treatment, these three participants had reached milestones such as…
GC301
Recent Posts
- It’s hard on my child when home infusions interrupt summer fun
- MRI scans show different muscle damage in different Pompe types
- Learning to be comfortable with the uncomfortable as a rare disease parent
- New GAA mutations destabilize key enzyme in Pompe disease: Study
- The things people say when they don’t know what to say